This study is aimed at investigating the efficacy of intraocular lens (IOL) implantation in patients suffering from glaucoma through meta-analysis of the previously published research. For this purpose, different literature databases were searched for identification of clinical studies published between January 2000 and January 2022 on evaluating IOL’s efficacy in treating glaucoma. RevMan 5.3 was used to conduct a meta-analysis of the pertinent data. The central anterior chamber depth (ACD), corneal endothelial cell counts, best-corrected visual acuity (BCVA), intraocular pressure (IOP), anti-glaucoma medications (AGM), and axial length (AL) changes were compared, and the incidence of postoperative complications was thoroughly evaluated. The Cochran chi-square test was used to examine the heterogeneity of the evaluation results. According to the inclusion and exclusion criteria, 20 studies included 948 glaucomatous eyes. IOP was significantly lower than before treatment ( MD = 8.64 , 95 CI: 5.75-11.53; Z = 5.86 , P < 0.0001 ), while ACD increased significantly ( MD = − 1.38 , 95 percent CI: -1.74-1.02; Z = 7.49 , P < 0.0001 ). The corneal endothelial cell counts were homogeneous ( MD = 225.08 , 95% CI: -64.17 to -514.33; Z = 1.53 , P = 0.20 ). AGM utilisation decreased ( MD = 1.43 , 95% CI: 0.752.12, Z = 4.09 , P < 0.0001 ). AL decreased significantly ( MD = 0.31 ; 95% CI: 0.09-0.54; Z = 2.71 ; P = 0.007 ). The incidence of complications remained insignificant after IOL treatment ( OR = 1.05 , 95% CI: 0.42 to 2.60; Z = 0.10 , P = 0.92 ; P = 0.92 ). These findings indicate that IOL treatment can significantly reduce intraocular pressure, glaucoma drug use, and aqueous level (AL) in glaucoma patients while increasing the depth of the central anterior chamber. This study offers a theoretical foundation for selecting glaucoma treatment methods.

Background Vision loss is a serious complication of hyaluronic acid filler injections, and long-term observations regarding the prognosis, particularly with angiography, is rare. Objectives This study aimed to investigate the long-term prognosis and living status of patients with visual defects due to hyaluronic acid filler injections. Methods Nine patients with vision loss caused by hyaluronic acid filler injections and receiving different treatments were included and followed up for 2–6 years after the accident. Follow-ups, including outpatient ophthalmologic examinations, were performed in this study. Results In our follow-up observation, all patients had reintegrated into society and work. The prognosis was similar for all hyaluronidase treatments, including retrobulbar injections and superselective ophthalmic artery thrombolysis. The facial appearance was not remarkably affected, and only three patients reported slight scarring. Ptosis disappeared in all the patients, and slight strabismus was found in five patients. However, vision improvement was very limited, even in the patients whose occluded retinal central artery received reperfusion. Conclusions Our long-term follow-up showed that the patients with vision loss caused by hyaluronic acid filler injections could reintegrate into society after treatment. Although the embolization of the retinal central artery led to reperfusion, vision was not restored, which further demonstrated the difficulty of recovering vision with the current treatment and the importance of prophylaxis. In the future, we envision developing autohydrolysis HA by incorporating hyaluronidase-containing stimuli-responsive nanoparticles and a dual-pipe syringe to address this catastrophic event.